vTv Therapeutics Inc. (VTVT)

Market Cap	375.35M +132.8%
Revenue (ttm)	36.84M +216,600.0%
Net Income	-4.76M
EPS	-0.42
Shares Out	12.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,732
Open	30.60
Previous Close	30.73
Day's Range	29.79 - 30.91
52-Week Range	19.50 - 44.00
Beta	0.29
Analysts	Strong Buy
Price Target	54.71 (+81.1%)
Est. Earnings	Nov 5, 2026

About VTVT

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to dev...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2015
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: VTVT
• Website: https://vtvtherapeutics.com

Analyst Summary

According to 7 analysts, the average rating for VTVT stock is "Strong Buy." The 12-month stock price target is $54.71, which is an increase of 81.10% from the latest price.

Price Target

$54.71

(81.10% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 26, 2026

Data Sources Report a data error